Literature DB >> 26158404

Dual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe Molecules.

Andrew K Urick1, Laura M L Hawk1, Melissa K Cassel1, Neeraj K Mishra1, Shuai Liu2, Neeta Adhikari3, Wei Zhang2, Camila O dos Santos4, Jennifer L Hall3, William C K Pomerantz1.   

Abstract

Bromodomain-containing protein dysregulation is linked to cancer, diabetes, and inflammation. Selective inhibition of bromodomain function is a newly proposed therapeutic strategy. We describe a (19)F NMR dual screening method for small molecule discovery using fluorinated tryptophan resonances on two bromodomain-containing proteins. The chemical shift dispersion of (19)F resonances within fluorine-labeled proteins enables the simultaneous analysis of two fluorinated bromodomains by NMR. A library of 229 small molecules was screened against the first bromodomain of Brd4 and the BPTF bromodomain. We report the first small molecule selective for BPTF over Brd4, termed AU1. The Kd = 2.8 μM for AU1, which is active in a cell-based reporter assay. No binding is detected with Brd4. Three new Brd4 inhibitors with submicromolar affinity were also discovered. Brd4 hits were validated in a thermal stability assay and potency determined via fluorescence anisotropy. The speed, ease of interpretation, and low protein concentration needed for protein-observed (19)F NMR experiments in a multiprotein format offers a new method to discover and characterize selective ligands for bromodomain-containing proteins.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26158404      PMCID: PMC4858447          DOI: 10.1021/acschembio.5b00483

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  38 in total

1.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes.

Authors:  Jagat C Borah; Shiraz Mujtaba; Ioannis Karakikes; Lei Zeng; Michaela Muller; Jigneshkumar Patel; Natasha Moshkina; Keita Morohashi; Weijia Zhang; Guillermo Gerona-Navarro; Roger J Hajjar; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2011-04-22

2.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand.

Authors:  Xinyi Huang
Journal:  J Biomol Screen       Date:  2003-02

3.  Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.

Authors:  Chun-Wa Chung; Anthony W Dean; James M Woolven; Paul Bamborough
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

4.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

Review 5.  Targeting bromodomains: epigenetic readers of lysine acetylation.

Authors:  Panagis Filippakopoulos; Stefan Knapp
Journal:  Nat Rev Drug Discov       Date:  2014-04-22       Impact factor: 84.694

6.  Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions.

Authors:  Alexander J Ruthenburg; Haitao Li; Thomas A Milne; Scott Dewell; Robert K McGinty; Melanie Yuen; Beatrix Ueberheide; Yali Dou; Tom W Muir; Dinshaw J Patel; C David Allis
Journal:  Cell       Date:  2011-05-19       Impact factor: 41.582

7.  Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking.

Authors:  Fleur M Ferguson; David M Dias; João P G L M Rodrigues; Hans Wienk; Rolf Boelens; Alexandre M J J Bonvin; Chris Abell; Alessio Ciulli
Journal:  Biochemistry       Date:  2014-10-15       Impact factor: 3.162

8.  Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations, and range of applicability.

Authors:  Claudio Dalvit; Paul E Fagerness; Daneen T A Hadden; Ronald W Sarver; Brian J Stockman
Journal:  J Am Chem Soc       Date:  2003-06-25       Impact factor: 15.419

9.  Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.

Authors:  Lewis R Vidler; Nathan Brown; Stefan Knapp; Swen Hoelder
Journal:  J Med Chem       Date:  2012-07-12       Impact factor: 7.446

10.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Authors:  Pietro Ciceri; Susanne Müller; Alison O'Mahony; Oleg Fedorov; Panagis Filippakopoulos; Jeremy P Hunt; Elisabeth A Lasater; Gabriel Pallares; Sarah Picaud; Christopher Wells; Sarah Martin; Lisa M Wodicka; Neil P Shah; Daniel K Treiber; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2014-03-02       Impact factor: 15.040

View more
  33 in total

1.  2-Fluorotyrosine is a valuable but understudied amino acid for protein-observed 19F NMR.

Authors:  Peter D Ycas; Nicole Wagner; Noelle M Olsen; Riqiang Fu; William C K Pomerantz
Journal:  J Biomol NMR       Date:  2019-11-23       Impact factor: 2.835

2.  Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors.

Authors:  Angela S Carlson; Huarui Cui; Anand Divakaran; Jorden A Johnson; Ryan M Brunner; William C K Pomerantz; Joseph J Topczewski
Journal:  ACS Med Chem Lett       Date:  2019-08-02       Impact factor: 4.345

3.  Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment.

Authors:  Clifford T Gee; Keith E Arntson; Andrew K Urick; Neeraj K Mishra; Laura M L Hawk; Andrea J Wisniewski; William C K Pomerantz
Journal:  Nat Protoc       Date:  2016-07-14       Impact factor: 13.491

4.  BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.

Authors:  Alex M Ayoub; Laura M L Hawk; Ryan J Herzig; Jiewei Jiang; Andrea J Wisniewski; Clifford T Gee; Peiliang Zhao; Jin-Yi Zhu; Norbert Berndt; Nana K Offei-Addo; Thomas G Scott; Jun Qi; James E Bradner; Timothy R Ward; Ernst Schönbrunn; Gunda I Georg; William C K Pomerantz
Journal:  J Med Chem       Date:  2017-06-07       Impact factor: 7.446

5.  Dual Labeling of the CBP/p300 KIX Domain for 19 F NMR Leads to Identification of a New Small-Molecule Binding Site.

Authors:  Clifford T Gee; Keith E Arntson; Edward J Koleski; Rachel Lynn Staebell; William C K Pomerantz
Journal:  Chembiochem       Date:  2018-04-06       Impact factor: 3.164

6.  Paramagnetic relaxation enhancement for protein-observed 19F NMR as an enabling approach for efficient fragment screening.

Authors:  Laura M L Hawk; Clifford T Gee; Andrew K Urick; Haitao Hu; William C K Pomerantz
Journal:  RSC Adv       Date:  2016-09-29       Impact factor: 3.361

7.  New inhibitors for the BPTF bromodomain enabled by structural biology and biophysical assay development.

Authors:  Peter D Ycas; Huda Zahid; Alice Chan; Noelle M Olson; Jorden A Johnson; Siva K Talluri; Ernst Schonbrunn; William C K Pomerantz
Journal:  Org Biomol Chem       Date:  2020-07-15       Impact factor: 3.876

Review 8.  Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.

Authors:  Nilesh Zaware; Ming-Ming Zhou
Journal:  Curr Opin Chem Biol       Date:  2017-07-06       Impact factor: 8.822

9.  Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to 1H CPMG Ligand-Observed NMR.

Authors:  Andrew K Urick; Luis Pablo Calle; Juan F Espinosa; Haitao Hu; William C K Pomerantz
Journal:  ACS Chem Biol       Date:  2016-10-05       Impact factor: 5.100

10.  Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.

Authors:  Anand Divakaran; Siva K Talluri; Alex M Ayoub; Neeraj K Mishra; Huarui Cui; John C Widen; Norbert Berndt; Jin-Yi Zhu; Angela S Carlson; Joseph J Topczewski; Ernst K Schonbrunn; Daniel A Harki; William C K Pomerantz
Journal:  J Med Chem       Date:  2018-10-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.